Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
BrainStorm Cell Therapeutics

BrainStorm Cell Therapeutics

A biotechnology company that develops stem cell therapies for the treatment of neurodegenerative diseases

Help us improve this page by adding information.
Visit our Writing Guide or this topic page for additional help.

Timeline

July 27, 2012
BrainStorm Cell Therapeutics raises a $206,910 seed round.

Funding Rounds

Patents

Further Resources

Title
Author
Link
Type
Date

BrainStorm Cell Therapeutics

April 27, 2018

BrainStorm Cell Therapeutics halfway through enrolling its Phase 3 ALS study

January 11, 2019

Brainstorm Cell Therapeutics updates on its progressive MS drug development trials

February 12, 2019

News

Title
Author
Date
Publisher
Description
Brainstorm Cell Therapeutics Inc
June 15, 2021
www.prnewswire.com:443
/PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today...
Heather McKenzie
May 4, 2021
BioSpace
There is also a tacit acknowledgment in the industry that the ALSFRS-R (revised) scale needs to evolve.
Brainstorm Cell Therapeutics Inc
April 19, 2021
www.prnewswire.com:443
/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today...
Nick Paul
March 24, 2021
FierceBiotech
BrainStorm Cell Therapeutics has presented phase 2 data on its stem cell therapy in patients with multiple sclerosis. The small, open-label clinical trial linked autologous therapy NurOwn to a 25% improvement in measures of mobility and dexterity in around 14% of patients.
Pomerantz LLP
March 3, 2021
www.prnewswire.com:443
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc. ("Brainstorm" or the "Company") (NASDAQ:...
SHOW MORE
Golden logo
By using this site, you agree to our Terms & Conditions.